Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 241

1.

Diagnosis of Beckwith-Wiedemann syndrome in children presenting with Wilms tumor.

MacFarland SP, Duffy KA, Bhatti TR, Bagatell R, Balamuth NJ, Brodeur GM, Ganguly A, Mattei PA, Surrey LF, Balis FM, Kalish JM.

Pediatr Blood Cancer. 2018 Jun 22:e27296. doi: 10.1002/pbc.27296. [Epub ahead of print]

PMID:
29932284
2.

Case Report: Nephron-sparing Surgery in a Patient With Bilateral Multifocal Wilms Tumor.

Bowen DK, Long CJ, Balis FM, Kolon TF.

Urology. 2018 Apr 25. pii: S0090-4295(18)30280-2. doi: 10.1016/j.urology.2018.03.024. [Epub ahead of print]

PMID:
29704588
3.

Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.

Kraft IL, Akshintala S, Zhu Y, Lei H, Derse-Anthony C, Dombi E, Steinberg SM, Lodish M, Waguespack SG, Kapustina O, Fox E, Balis FM, Merino MJ, Meltzer PS, Glod JW, Shern JF, Widemann BC.

Clin Cancer Res. 2018 Feb 15;24(4):753-765. doi: 10.1158/1078-0432.CCR-17-2101. Epub 2017 Nov 29.

PMID:
29187393
4.

Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.

Ramsey LB, Balis FM, O'Brien MM, Schmiegelow K, Pauley JL, Bleyer A, Widemann BC, Askenazi D, Bergeron S, Shirali A, Schwartz S, Vinks AA, Heldrup J.

Oncologist. 2018 Jan;23(1):52-61. doi: 10.1634/theoncologist.2017-0243. Epub 2017 Oct 27.

5.

Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group.

Gore L, Ivy SP, Balis FM, Rubin E, Thornton K, Donoghue M, Roberts S, Bruinooge S, Ersek J, Goodman N, Schenkel C, Reaman G.

J Clin Oncol. 2017 Nov 20;35(33):3781-3787. doi: 10.1200/JCO.2017.74.4144. Epub 2017 Oct 2.

PMID:
28968169
6.

Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force.

Balis FM, Womer RB, Berg S, Winick N, Adamson PC, Fox E; Children's Oncology Group Chemotherapy Standardization Task Force.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26636. Epub 2017 May 16.

PMID:
28509433
7.

First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium.

Balis FM, Thompson PA, Mosse YP, Blaney SM, Minard CG, Weigel BJ, Fox E.

Cancer Chemother Pharmacol. 2017 Jan;79(1):181-187. doi: 10.1007/s00280-016-3220-6. Epub 2016 Dec 28.

8.

15-0600-Dr. Fox's response to letter to the editor.

Fox E, Balis FM.

Cancer Chemother Pharmacol. 2016 Nov;78(5):1099-1100. Epub 2016 Oct 11. No abstract available.

9.

Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors.

Fox E, Widemann BC, Pastakia D, Chen CC, Yang SX, Cole D, Balis FM.

Cancer Chemother Pharmacol. 2015 Dec;76(6):1273-83. doi: 10.1007/s00280-015-2845-1. Epub 2015 Oct 20.

PMID:
26486517
10.

Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group.

Stieglitz E, Ward AF, Gerbing RB, Alonzo TA, Arceci RJ, Liu YL, Emanuel PD, Widemann BC, Cheng JW, Jayaprakash N, Balis FM, Castleberry RP, Bunin NJ, Loh ML, Cooper TM.

Pediatr Blood Cancer. 2015 Apr;62(4):629-36. doi: 10.1002/pbc.25342. Epub 2014 Dec 8.

11.

Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.

Desai AV, Fox E, Smith LM, Lim AP, Maris JM, Balis FM.

Cancer Chemother Pharmacol. 2014 Nov;74(5):1047-55. doi: 10.1007/s00280-014-2575-9. Epub 2014 Sep 12.

PMID:
25212536
12.

Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Widemann BC, Babovic-Vuksanovic D, Dombi E, Wolters PL, Goldman S, Martin S, Goodwin A, Goodspeed W, Kieran MW, Cohen B, Blaney SM, King A, Solomon J, Patronas N, Balis FM, Fox E, Steinberg SM, Packer RJ.

Pediatr Blood Cancer. 2014 Sep;61(9):1598-602. doi: 10.1002/pbc.25041. Epub 2014 Apr 22.

PMID:
24753394
13.

Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.

Nella AA, Lodish MB, Fox E, Balis FM, Quezado MM, Whitcomb PO, Derdak J, Kebebew E, Widemann BC, Stratakis CA.

J Clin Endocrinol Metab. 2014 Sep;99(9):3055-9. doi: 10.1210/jc.2013-4340. Epub 2014 Mar 11.

14.

Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Widemann BC, Dombi E, Gillespie A, Wolters PL, Belasco J, Goldman S, Korf BR, Solomon J, Martin S, Salzer W, Fox E, Patronas N, Kieran MW, Perentesis JP, Reddy A, Wright JJ, Kim A, Steinberg SM, Balis FM.

Neuro Oncol. 2014 May;16(5):707-18. doi: 10.1093/neuonc/nou004. Epub 2014 Feb 4.

15.

Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621).

Fox E, Mosse' YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn SL, Adamson PC, London WB, Maris JM, Balis FM.

Pediatr Blood Cancer. 2014 Jun;61(6):990-6. doi: 10.1002/pbc.24900. Epub 2013 Dec 18.

16.

Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.

Fox E, Widemann BC, Chuk MK, Marcus L, Aikin A, Whitcomb PO, Merino MJ, Lodish M, Dombi E, Steinberg SM, Wells SA, Balis FM.

Clin Cancer Res. 2013 Aug 1;19(15):4239-48. doi: 10.1158/1078-0432.CCR-13-0071. Epub 2013 Jun 13.

17.

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

Mossé YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, Ingle AM, Ahern C, Adamson PC, Blaney SM.

Lancet Oncol. 2013 May;14(6):472-80. doi: 10.1016/S1470-2045(13)70095-0. Epub 2013 Apr 16.

18.

A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.

Widemann BC, Kim A, Fox E, Baruchel S, Adamson PC, Ingle AM, Glade Bender J, Burke M, Weigel B, Stempak D, Balis FM, Blaney SM.

Clin Cancer Res. 2012 Nov 1;18(21):6011-22. doi: 10.1158/1078-0432.CCR-11-3284. Epub 2012 Sep 7.

19.

Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.

Kim A, Dombi E, Tepas K, Fox E, Martin S, Wolters P, Balis FM, Jayaprakash N, Turkbey B, Muradyan N, Choyke PL, Reddy A, Korf B, Widemann BC.

Pediatr Blood Cancer. 2013 Mar;60(3):396-401. doi: 10.1002/pbc.24281. Epub 2012 Sep 7.

PMID:
22961690
20.

A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors.

Chuk MK, Aikin A, Whitcomb T, Widemann BC, Zannikos P, Bayever E, Balis FM, Fox E.

Pediatr Blood Cancer. 2012 Nov;59(5):865-9. doi: 10.1002/pbc.24201. Epub 2012 Jul 27.

21.

Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin.

Murphy RF, Komlodi-Pasztor E, Robey R, Balis FM, Farrell NP, Fojo T.

Cell Cycle. 2012 Mar 1;11(5):963-73. doi: 10.4161/cc.11.5.19447. Epub 2012 Mar 1.

22.

A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.

Warren KE, Gururangan S, Geyer JR, McLendon RE, Poussaint TY, Wallace D, Balis FM, Berg SL, Packer RJ, Goldman S, Minturn JE, Pollack IF, Boyett JM, Kun LE.

J Neurooncol. 2012 Feb;106(3):643-9. doi: 10.1007/s11060-011-0709-z. Epub 2011 Oct 4.

23.

Automated volumetric growth plate measurement using magnetic resonance imaging for monitoring skeletal toxicity in children treated on investigational drug trials.

Kim A, Dombi E, Solomon J, Fox E, Balis FM, Widemann BC.

Clin Cancer Res. 2011 Sep 15;17(18):5982-90. doi: 10.1158/1078-0432.CCR-10-2259. Epub 2011 Aug 1.

24.

The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates.

Marcus L, Murphy R, Fox E, McCully C, Cruz R, Warren KE, Meyer T, McNiff E, Balis FM, Widemann BC.

Cancer Chemother Pharmacol. 2012 Jan;69(1):247-52. doi: 10.1007/s00280-011-1659-z. Epub 2011 Jun 26.

PMID:
21706317
25.

Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium.

Aplenc R, Blaney SM, Strauss LC, Balis FM, Shusterman S, Ingle AM, Agrawal S, Sun J, Wright JJ, Adamson PC.

J Clin Oncol. 2011 Mar 1;29(7):839-44. doi: 10.1200/JCO.2010.30.7231. Epub 2011 Jan 24.

26.

Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors.

Bagatell R, Herzog CE, Trippett TM, Grippo JF, Cirrincione-Dall G, Fox E, Macy M, Bish J, Whitcomb P, Aikin A, Wright G, Yurasov S, Balis FM, Gore L.

Clin Cancer Res. 2011 Feb 1;17(3):611-9. doi: 10.1158/1078-0432.CCR-10-1731. Epub 2010 Dec 2.

27.

Commentary.

Fox E, Balis FM.

Clin Chem. 2010 Dec;56(12):1795. doi: 10.1373/clinchem.2010.153601. No abstract available.

28.

A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.

Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM, Steinberg SM, Fojo T, Bates SE.

Clin Cancer Res. 2011 Feb 1;17(3):569-80. doi: 10.1158/1078-0432.CCR-10-1725. Epub 2010 Nov 16.

29.

The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.

Kim A, McCully C, Cruz R, Cole DE, Fox E, Balis FM, Widemann BC.

Invest New Drugs. 2012 Apr;30(2):524-8. doi: 10.1007/s10637-010-9585-1. Epub 2010 Nov 12.

PMID:
21072558
30.

A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.

Fox E, Aplenc R, Bagatell R, Chuk MK, Dombi E, Goodspeed W, Goodwin A, Kromplewski M, Jayaprakash N, Marotti M, Brown KH, Wenrich B, Adamson PC, Widemann BC, Balis FM.

J Clin Oncol. 2010 Dec 10;28(35):5174-81. doi: 10.1200/JCO.2010.30.9674. Epub 2010 Nov 8.

31.

Dexrazoxane as a cardioprotectant in children receiving anthracyclines.

Sepe DM, Ginsberg JP, Balis FM.

Oncologist. 2010;15(11):1220-6. doi: 10.1634/theoncologist.2010-0162. Epub 2010 Nov 4.

32.

Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group.

Widemann BC, Arceci RJ, Jayaprakash N, Fox E, Zannikos P, Goodspeed W, Goodwin A, Wright JJ, Blaney SM, Adamson PC, Balis FM.

Pediatr Blood Cancer. 2011 Feb;56(2):226-33. doi: 10.1002/pbc.22775. Epub 2010 Sep 21.

33.

Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model.

Chuk MK, Cole DE, McCully C, Loktionova NA, Pegg AE, Parker RJ, Pauly G, Widemann BC, Balis FM, Fox E.

Cancer Chemother Pharmacol. 2011 Jun;67(6):1291-7. doi: 10.1007/s00280-010-1407-9. Epub 2010 Aug 20.

PMID:
20725726
34.

Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.

Widemann BC, Balis FM, Kim A, Boron M, Jayaprakash N, Shalabi A, O'Brien M, Eby M, Cole DE, Murphy RF, Fox E, Ivy P, Adamson PC.

J Clin Oncol. 2010 Sep 1;28(25):3979-86. doi: 10.1200/JCO.2009.25.4540. Epub 2010 Aug 2.

35.

Pediatric phase I trial design using maximum target inhibition as the primary endpoint.

Meany H, Balis FM, Aikin A, Whitcomb P, Murphy RF, Steinberg SM, Widemann BC, Fox E.

J Natl Cancer Inst. 2010 Jun 16;102(12):909-12. doi: 10.1093/jnci/djq174. Epub 2010 May 11.

36.

Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group.

Jacobs S, Fox E, Krailo M, Hartley G, Navid F, Wexler L, Blaney SM, Goodwin A, Goodspeed W, Balis FM, Adamson PC, Widemann BC.

Clin Cancer Res. 2010 Jan 15;16(2):750-4. doi: 10.1158/1078-0432.CCR-09-1906. Epub 2010 Jan 12.

37.

Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors.

Fox E, Maris JM, Cohn SL, Goodspeed W, Goodwin A, Kromplewski M, Medina D, Xiong H, Krivoshik A, Widemann B, Adamson PC, Balis FM.

Cancer Chemother Pharmacol. 2010 Sep;66(4):737-43. doi: 10.1007/s00280-009-1218-z. Epub 2010 Jan 1.

PMID:
20044751
38.

Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas.

Fox E, Widemann BC, Hawkins DS, Jayaprakash N, Dagher R, Aikin AA, Bernstein D, Long L, Mackall C, Helman L, Steinberg SM, Balis FM.

Clin Cancer Res. 2009 Dec 1;15(23):7361-7. doi: 10.1158/1078-0432.CCR-09-0761. Epub 2009 Nov 17.

39.

Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.

Kim A, Gillespie A, Dombi E, Goodwin A, Goodspeed W, Fox E, Balis FM, Widemann BC.

Neurology. 2009 Oct 20;73(16):1273-9. doi: 10.1212/WNL.0b013e3181bd1326.

40.

Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro.

Meany HJ, Sackett DL, Maris JM, Ward Y, Krivoshik A, Cohn SL, Steinberg SM, Balis FM, Fox E.

Pediatr Blood Cancer. 2010 Jan;54(1):47-54. doi: 10.1002/pbc.22267.

41.

Trabectedin.

Chuk MK, Balis FM, Fox E.

Oncologist. 2009 Aug;14(8):794-9. doi: 10.1634/theoncologist.2009-0104. Epub 2009 Aug 14. Review. No abstract available. Erratum in: Oncologist. 2009 Sep;14(9):949.

42.

Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates.

Jacobs S, McCully CL, Murphy RF, Bacher J, Balis FM, Fox E.

Cancer Chemother Pharmacol. 2010 Apr;65(5):817-24. doi: 10.1007/s00280-009-1085-7. Epub 2009 Aug 7.

PMID:
19662415
43.

Sorafenib and sunitinib.

Kim A, Balis FM, Widemann BC.

Oncologist. 2009 Aug;14(8):800-5. doi: 10.1634/theoncologist.2009-0088. Epub 2009 Aug 1. Review. No abstract available. Erratum in: Oncologist. 2009 Sep;14(9):949.

44.

The legacy of cancer therapy in children.

Fox E, Citrin D, Balis FM.

J Natl Cancer Inst. 2009 Aug 19;101(16):1105-7. doi: 10.1093/jnci/djp238. Epub 2009 Jul 31. No abstract available.

PMID:
19648512
45.

Conformational heterogeneity and quasi-static self-quenching in DNA containing a fluorescent guanine analogue, 3MI or 6MI.

Wojtuszewski Poulin K, Smirnov AV, Hawkins ME, Balis FM, Knutson JR.

Biochemistry. 2009 Sep 22;48(37):8861-8. doi: 10.1021/bi9003414.

46.

Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors.

Meany HJ, Warren KE, Fox E, Cole DE, Aikin AA, Balis FM.

Cancer Chemother Pharmacol. 2009 Dec;65(1):137-42. doi: 10.1007/s00280-009-1015-8. Epub 2009 May 9.

PMID:
19430790
47.

Clinical drug development for childhood cancers.

Balis FM, Fox E, Widemann BC, Adamson PC.

Clin Pharmacol Ther. 2009 Feb;85(2):127-9. doi: 10.1038/clpt.2008.237. No abstract available.

PMID:
19151636
48.

Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors.

Widemann BC, Goodspeed W, Goodwin A, Fojo T, Balis FM, Fox E.

J Clin Oncol. 2009 Feb 1;27(4):550-6. doi: 10.1200/JCO.2008.17.6644. Epub 2008 Dec 15.

49.

Characteristics and outcome of pediatric patients enrolled in phase I oncology trials.

Kim A, Fox E, Warren K, Blaney SM, Berg SL, Adamson PC, Libucha M, Byrley E, Balis FM, Widemann BC.

Oncologist. 2008 Jun;13(6):679-89. doi: 10.1634/theoncologist.2008-0046.

50.

A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.

Fox E, Maris JM, Widemann BC, Goodspeed W, Goodwin A, Kromplewski M, Fouts ME, Medina D, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM.

Clin Cancer Res. 2008 Feb 15;14(4):1111-5. doi: 10.1158/1078-0432.CCR-07-4097.

Supplemental Content

Loading ...
Support Center